The field of myeloma and chronic lymphocytic leukaemia is changing at pace. Due to significant advances in technology, particularly in genomics, our understanding of normal and neoplastic haemopoiesis is constantly improving. However the real challenge is how these technological advances and genomic information can be transferred from the laboratory to the clinical management of the individual patient. The study day will focus on the recent advances seen within myeloma, chronic lymphocytic leukaemia and myeloproliferations and how diagnostic advances guide the individual patient pathway.
Programme- to be updated 2021
Register – Registration is to open soon